BASF is targeting the pharma industry at ChemSpec this June with new intermediates, catalysts and raw materials that promise to make customers' syntheses less complex and time-consuming as well as more cost-effective.
The company's Intermediates operating division will be out in full force in the trade show, displaying a broad portfolio of reagents, solvents and protecting groups for chemical synthesis, including chiral amines, alcohols, epoxides and acids.
Also showcased will be a new process based on dehydrogenase, a bio-catalyst, for making new optically active styrene oxides and aliphatic alcohols.
Now established at the production scale, BASF claims this new process can produce outstandingly pure substances that serve as important building blocks for the pharmaceutical industry.
BASF also has one of the most extensive technology platforms for manufacturing achiral specialties, including specialty amines and heterocycles.
"The Intermediates Division makes hundreds of reagents, solvents andbuilding blocks for the pharmaceutical industry; Piperazine, Huenig base, which we now make to improved specifications, and THF, are excellent examples," BASF spokeswoman Vanessa Holzhaeuser told In-PharmaTechnologist.com.
"Major pharma interests clearly pertain to our ChiPros, including new products like S-2-butanol or R-3-chlorostyrene oxide, which we produce by dehydrogenase technology, and chiral amines such as R- and S-naphthylethylamine."
The brand name ChiPros refers to BASF's chiral products, including amines, alcohols, epoxides and acids.
The Inorganics operating division of the chemical company will also be represented, targeting the pharma industry with sodium and potassium alcoholates and borane complexes, boron trifluoride gas and complexes, hydroxylamine free base, hydroxylamine salts and derivatives and highly pure inorganic salts (e.g. sulphites, nitrites).